Ser84
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser84  -  VGLL1 (human)

Site Information
PNQWRYSsPWTKPQP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1870773106

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
gastric cancer ( 1 ) , gastric carcinoma ( 1 )
Relevant cell line - cell type - tissue:
AGS (gastric) ( 1 ) , HEK293T (epithelial) ( 1 ) , MKN-28 (gastric) ( 1 ) , NUGC-3 (gastric) ( 1 )

Upstream Regulation
Putative in vivo kinases:
RSK2 (human) ( 1 )
Treatments:
siRNA ( 1 ) , TGF-beta ( 1 ) , U0126 ( 1 )

Downstream Regulation
Effects of modification on VGLL1:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , transcription, induced ( 1 )
Induce interaction with:
TEAD4 (human) ( 1 )

References 

1

Im JY, et al. (2020) VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling. Biochim Biophys Acta Mol Cell Res 1868, 118892
33069758   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.